Mesoblast Ltd
ASX:MSB

Watchlist Manager
Mesoblast Ltd Logo
Mesoblast Ltd
ASX:MSB
Watchlist
Price: 1.505 AUD 1.35% Market Closed
Market Cap: 1.7B AUD
Have any thoughts about
Mesoblast Ltd?
Write Note

Intrinsic Value

The intrinsic value of one MSB stock under the Base Case scenario is 3.187 AUD. Compared to the current market price of 1.505 AUD, Mesoblast Ltd is Undervalued by 53%.

The Intrinsic Value is calculated as the average of DCF and Relative values:

MSB Intrinsic Value
3.187 AUD
Undervaluation 53%
Intrinsic Value
Price
Base Case Scenario

Valuation Backtest
Mesoblast Ltd

Backtest Intrinsic Value
Dive into the past to invest in the future

Uncover deeper insights with the Valuation Backtest. Learn how current stock valuations stack up against historical averages to gauge true investment potential.

Start backtest now and learn if your stock is truly undervalued or overvalued!

Run Backtest
Backtest Conclusion
Very Attractive
Current Valuation
+45%
Avg Valuation
-12%
Worst Valuation
-49%
Best Valuation
+45%

Stock is trading at its lowest valuation over the past 5 years.

Backtest Example
Register to View Results
Register to View Results

To access the results of this valuation backtest, please register an account with us. Registration is quick and gives you instant access to insights on 3 stocks per week for free.

Backtest Unavailable

The backtest for MSB cannot be conducted due to limitations such as insufficient data or other constraints. Please select a different stock or adjust your settings.

Backtest In Progress...
Backtest In Progress...
How do you feel about MSB?
Bearish
Neutral
Bullish

Fundamental Analysis

Company Quality
No Indicators Selected
Select Indicators

Select up to 3 indicators:

Insider Trading
0-3
Months
0-6
Months
0-12
Months
0-36
Months
No Periods Selected
Select Periods

Select up to 2 periods:

Investment Journal
AI Assistant
AI Assistant
Ask me anything about Mesoblast Ltd

Provide an overview of the primary business activities
of Mesoblast Ltd.

What unique competitive advantages
does Mesoblast Ltd hold over its rivals?

What risks and challenges
does Mesoblast Ltd face in the near future?

Has there been any significant insider trading activity
in Mesoblast Ltd recently?

Summarize the latest earnings call
of Mesoblast Ltd.

Is it considered overvalued or undervalued
based on the latest financial data?

Show all valuation multiples
for Mesoblast Ltd.

Provide P/S
for Mesoblast Ltd.

Provide P/E
for Mesoblast Ltd.

Provide P/OCF
for Mesoblast Ltd.

Provide P/FCFE
for Mesoblast Ltd.

Provide P/B
for Mesoblast Ltd.

Provide EV/S
for Mesoblast Ltd.

Provide EV/GP
for Mesoblast Ltd.

Provide EV/EBITDA
for Mesoblast Ltd.

Provide EV/EBIT
for Mesoblast Ltd.

Provide EV/OCF
for Mesoblast Ltd.

Provide EV/FCFF
for Mesoblast Ltd.

Provide EV/IC
for Mesoblast Ltd.

Show me price targets
for Mesoblast Ltd made by professional analysts.

What are the Revenue projections
for Mesoblast Ltd?

How accurate were the past Revenue estimates
for Mesoblast Ltd?

What are the Net Income projections
for Mesoblast Ltd?

How accurate were the past Net Income estimates
for Mesoblast Ltd?

What are the EPS projections
for Mesoblast Ltd?

How accurate were the past EPS estimates
for Mesoblast Ltd?

What are the EBIT projections
for Mesoblast Ltd?

How accurate were the past EBIT estimates
for Mesoblast Ltd?

Compare the revenue forecasts
for Mesoblast Ltd with those of its competitors based on recent analyst estimates.

Compare the intrinsic valuations
of Mesoblast Ltd and its key competitors using the latest financial data.

Compare historical revenue growth rates
of Mesoblast Ltd against its competitors.

Analyze the profit margins
(gross, operating, and net) of Mesoblast Ltd compared to its peers.

Compare the P/E ratios
of Mesoblast Ltd against its peers.

Discuss the investment returns and shareholder value creation
comparing Mesoblast Ltd with its peers.

Analyze the financial leverage
of Mesoblast Ltd compared to its main competitors.

Show all profitability ratios
for Mesoblast Ltd.

Provide ROE
for Mesoblast Ltd.

Provide ROA
for Mesoblast Ltd.

Provide ROIC
for Mesoblast Ltd.

Provide ROCE
for Mesoblast Ltd.

Provide Gross Margin
for Mesoblast Ltd.

Provide Operating Margin
for Mesoblast Ltd.

Provide Net Margin
for Mesoblast Ltd.

Provide FCF Margin
for Mesoblast Ltd.

Show all solvency ratios
for Mesoblast Ltd.

Provide D/E Ratio
for Mesoblast Ltd.

Provide D/A Ratio
for Mesoblast Ltd.

Provide Interest Coverage Ratio
for Mesoblast Ltd.

Provide Altman Z-Score Ratio
for Mesoblast Ltd.

Provide Quick Ratio
for Mesoblast Ltd.

Provide Current Ratio
for Mesoblast Ltd.

Provide Cash Ratio
for Mesoblast Ltd.

What is the historical Revenue growth
over the last 5 years for Mesoblast Ltd?

What is the historical Net Income growth
over the last 5 years for Mesoblast Ltd?

What is the current Free Cash Flow
of Mesoblast Ltd?

Discuss the annual earnings per share (EPS)
trend over the past five years for Mesoblast Ltd.

Financials
Annual
Quarterly
TTM
Annual
Quarterly
TTM

Balance Sheet Decomposition
Mesoblast Ltd

Current Assets 86.5m
Cash & Short-Term Investments 62.6m
Receivables 3.4m
Other Current Assets 20.5m
Non-Current Assets 582.7m
Long-Term Investments 1m
PP&E 3.8m
Intangibles 575.7m
Other Non-Current Assets 2.1m
Current Liabilities 73.2m
Accounts Payable 7.1m
Accrued Liabilities 7.4m
Other Current Liabilities 58.7m
Non-Current Liabilities 115.6m
Long-Term Debt 102.4m
Other Non-Current Liabilities 13.1m
Efficiency

Earnings Waterfall
Mesoblast Ltd

Revenue
5.9m USD
Cost of Revenue
-15.7m USD
Gross Profit
-9.8m USD
Operating Expenses
-57.1m USD
Operating Income
-66.9m USD
Other Expenses
-21.1m USD
Net Income
-88m USD

Free Cash Flow Analysis
Mesoblast Ltd

Last Value
3-Years Average
FCF Margin
Conversion Rate
Fundamental Scores

MSB Profitability Score
Profitability Due Diligence

Mesoblast Ltd's profitability score is 21/100. The higher the profitability score, the more profitable the company is.

Exceptional Revenue Growth Forecast
ROIC is Increasing
Declining ROE
Negative 3-Years Revenue Growth
21/100
Profitability
Score

Mesoblast Ltd's profitability score is 21/100. The higher the profitability score, the more profitable the company is.

MSB Solvency Score
Solvency Due Diligence

Mesoblast Ltd's solvency score is 58/100. The higher the solvency score, the more solvent the company is.

Long-Term Solvency
Low D/E
Short-Term Solvency
Positive Net Debt
58/100
Solvency
Score

Mesoblast Ltd's solvency score is 58/100. The higher the solvency score, the more solvent the company is.

Wall St
Price Targets

MSB Price Targets Summary
Mesoblast Ltd

Wall Street analysts forecast MSB stock price to rise over the next 12 months.

According to Wall Street analysts, the average 1-year price target for MSB is 1.748 AUD with a low forecast of 1.111 AUD and a high forecast of 2.741 AUD.

Lowest
Price Target
1.111 AUD
26% Downside
Average
Price Target
1.748 AUD
16% Upside
Highest
Price Target
2.741 AUD
82% Upside
View Analyst Estimates
View Analyst Estimates
Want to learn more about Wall St estimates for MSB?

Click here to dive deeper.

Dividends

Mesoblast Ltd
does not pay dividends
Shareholder Yield

Current shareholder yield for MSB is .

Shareholder yield represents the total return a company provides to its shareholders, calculated as the sum of dividend yield, buyback yield, and debt paydown yield. What is shareholder yield?

Shareholder Yield
Dividend Yield
No dividends
Buyback Yield
Lowest
Average
Highest
Debt Paydown Yield
Lowest
Average
Highest

Ownership

MSB Insider Trading
Buy and sell transactions by insiders

Cumulative Transactions Amount
Period Sold Bought Net
3 Months
6 Months
9 Months
12 Months
Why is insider trading important?

MSB News

Other Videos

Profile

Mesoblast Ltd Logo
Mesoblast Ltd

Country

Australia

Industry

Biotechnology

Market Cap

1.7B AUD

Dividend Yield

0%

Description

Mesoblast Ltd. is a biopharmaceutical company, which engages in the research, development, and market of mesenchymal lineage adult stem cell technology platform. The company is headquartered in Melbourne, Victoria and currently employs 83 full-time employees. The company went IPO on 2004-12-16. The firm is using its mesenchymal lineage cell technology platform to develop and commercialize allogeneic cellular medicines to treat complex inflammatory diseases. Its product candidate includes Remestemcel-L ((RYONCIL) for the treatment of steroid-refractory acute graft versus host disease (SR-aGVHD), Rexlemestrocel-L (REVASCOR) for the advanced chronic heart failure (CHF) and MPC-06-ID for the treatment of chronic low back pain caused by disc degeneration (CLBP). Its product candidate MPC-150-IM for the treatment or prevention of chronic heart failure and MPC-25-IC for the treatment or prevention of acute myocardial infarction. Its product candidate also includes MPC-300-IV for the treatment of biologic-refractory rheumatoid arthritis and diabetic nephropathy.

Contact

VICTORIA
Melbourne
L 38 55 Collins St
+61396396036.0
www.mesoblast.com

IPO

2004-12-16

Employees

83

Officers

Founder, CEO, MD, Chairman of Scientific Advisory Board & Executive Director
Dr. Silviu Itescu FACP, FACRA, FRACP, MBBS (Hons)
Chief Medical Officer & Executive Director
Dr. Eric A. Rose M.D.
Interim Chief Finance Officer
Mr. Andrew Chaponnel B.Com.
General Counsel & Corporate Executive
Mr. Peter T. Howard B.Sc., L.L.B., LLB (Hons)
Scientific Advisor to the Chief Executive Officer
Dr. Paul J. Simmons BSc, Ph.D.
Head of Regulatory Affairs & Quality Management
Ms. Geraldine Storton B.Sc., M.B.A., MMS
Show More
Head of Manufacturing
Mr. Justin Horst B.S.
Senior VP & Head of Translational Research
Dr. Fiona See Ph.D.
Joint Company Secretary
Mr. Paul Hughes BPHARM
Show Less

See Also

Discover More
What is the Intrinsic Value of one MSB stock?

The intrinsic value of one MSB stock under the Base Case scenario is 3.187 AUD.

Is MSB stock undervalued or overvalued?

Compared to the current market price of 1.505 AUD, Mesoblast Ltd is Undervalued by 53%.

Back to Top